Your browser doesn't support javascript.
loading
Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend.
Locy, Hanne; de Mey, Sven; de Mey, Wout; De Ridder, Mark; Thielemans, Kris; Maenhout, Sarah K.
Afiliação
  • Locy H; Laboratory of Molecular and Cellular Therapy (LMCT), Vrije Universiteit Brussel, Brussels, Belgium.
  • de Mey S; Department of Radiotherapy, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
  • de Mey W; Laboratory of Molecular and Cellular Therapy (LMCT), Vrije Universiteit Brussel, Brussels, Belgium.
  • De Ridder M; Department of Radiotherapy, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
  • Thielemans K; Laboratory of Molecular and Cellular Therapy (LMCT), Vrije Universiteit Brussel, Brussels, Belgium.
  • Maenhout SK; Laboratory of Molecular and Cellular Therapy (LMCT), Vrije Universiteit Brussel, Brussels, Belgium.
Front Immunol ; 9: 2909, 2018.
Article em En | MEDLINE | ID: mdl-30619273
ABSTRACT
Immunotherapy, where the patient's own immune system is exploited to eliminate tumor cells, has become one of the most prominent new cancer treatment options in the last decade. The main hurdle for classical cancer vaccines is the need to identify tumor- and patient specific antigens to include in the vaccine. Therefore, in situ vaccination represents an alternative and promising approach. This type of immunotherapy involves the direct intratumoral administration of different immunomodulatory agents and uses the tumor itself as the source of antigen. The ultimate aim is to convert an immunodormant tumor microenvironment into an immunostimulatory one, enabling the immune system to eradicate all tumor lesions in the body. In this review we will give an overview of different strategies, which can be exploited for the immunomodulation of the tumor microenvironment and their emerging role in the treatment of cancer patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunomodulação / Microambiente Tumoral / Imunoterapia / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Bélgica

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunomodulação / Microambiente Tumoral / Imunoterapia / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Front Immunol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Bélgica